Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-03-20

Benitec Biopharma (BNTC)

CEO Jerel Banks was paid $25,865,036 in fiscal year 2025, ↑ up 824.1% from fiscal year 2024 (SEC filing 0001193125-25-239131 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$25,865,036 ↑
Jerel Banks total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
77.73%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jerel Banks (Chairman and Chief Executive Officer), FY2025 total compensation $25,865,036 (base salary $661,100) [exec_comp, SEC accession 0001193125-25-239131, filed 2025-10-14]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jerel Banks$661,100$366,850$0$24,795,540$0$0$41,546$25,865,036
Chairman and Chief Executive Officer
Megan Boston445,610175,00007,728,48000250,2038,599,293
Chief Financial Officer, Secretary
Sophie Mukadam340,846200,00003,175,8000058,7473,775,393
Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jerel Banks$25,865,036$2,798,977$918,725↑ +23,066,059
Megan Boston8,599,293———
Sophie Mukadam3,775,393———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Benitec Biopharma's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BNTC reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against BNTC
No companies currently name BNTC as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Jerel BanksCEO$25,865,036
Megan BostonCFO$8,599,293
Sophie MukadamCOO$3,775,393
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Edward F. SmithIndependent Director$424,910
J. Kevin BuchiIndependent Director$432,410
Kishen MehtaIndependent Director$368,410
Peter FrancisIndependent Director$426,993
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Megan BostonOption2,9993.91—
BanksOption311,0365.21—
Sophie MukadamOption262,50012—
Sophie MukadamOption66,6675.21—
BanksOption6,9973.91—
BanksOption2,021,25012.18—
Megan BostonOption630,00012.18—
Megan BostonOption133,3365.21—
Sophie MukadamOption1,7653.91—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's named executive officer compensation program is designed to incentivize our named executive officers to grow our business and further link the interests of our named executive officers with our stockholders. We provide our named executive officers with an annual base salary as a fixed, stable form of compensation, certain cash incentive opportunities as noted below to reward achievement of short-term goals, and, in prior fiscal years, we have granted our named executive officers stock options with multi-year vesting schedules to further align their compensation with our stockholders' long-term interests.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-12-0117,239,3394,939,68672,52377.73%Passed
20242024-12-0417,307,6806,14814,55999.96%Passed
20232023-12-061,327,85247,4304,49396.24%Passed
20222022-12-0713,411,245396,01614,48797.03%Passed
20212021-12-083,429,224144,20834,97595.03%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-12-0177.73%a
20242024-12-0499.96%b
20232023-12-0696.24%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "AGAINST" Proposal 2, Proposal 3, and Proposal 4, and broker non-votes will have no effect on the results of Proposals 2, 3, or 4.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
J. Kevin BuchiIndependent · Audit (Chair) · Compensation · Nominating/Governance$64,000$0$368,410—$0$432,410
Peter FrancisIndependent · Audit · Compensation (Chair) · Nominating/Governance (Chair)52,5420368,410—6,041426,993
Edward F. SmithIndependent · Audit · Compensation · Nominating/Governance56,5000368,410—0424,910
Kishen MehtaIndependent · Nominating/Governance00368,410—0368,410
Dr. Jerel BanksEmployee director—————0
Megan BostonEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 10,000 / 7,500
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$173,042
Equity awards (grant-date value)$0
All other compensation$6,041
Total cost of the board$179,083

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Benitec Biopharma2025Jerel Banks$661,100$0$24,795,540$0$25,865,036

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Benitec Biopharma in fiscal 2025?
As disclosed, Jerel Banks (Chairman and Chief Executive Officer) was the highest-paid executive at Benitec Biopharma in fiscal 2025, with total compensation of $25,865,036.
How did shareholders vote on Benitec Biopharma's executive compensation?
As disclosed, 77.73% of shareholders supported Benitec Biopharma's executive compensation in the latest say-on-pay vote.
How much does Benitec Biopharma spend in total on board compensation for fiscal 2025?
As disclosed, Benitec Biopharma reported total board compensation of $179,083 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jerel BanksDEF 14A2025-10-140001193125-25-239131Section “Summary Compensation Table”. As printed: 25,865,036. Filing ↗machine: r2 · c22 · span 187662–187672
2Section 01, Megan BostonDEF 14A2025-10-140001193125-25-239131Section “Summary Compensation Table”. As printed: 8,599,293. Filing ↗machine: r4 · c22 · span 191005–191014
3Section 01, Sophie MukadamDEF 14A2025-10-140001193125-25-239131Section “Summary Compensation Table”. As printed: 3,775,393. Filing ↗machine: r6 · c22 · span 194351–194360
4Section 07, pay ratio10-K/A2026-03-200001193125-26-117604Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 08, J. Kevin BuchiDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 432,410. Filing ↗machine: span 303534–303541
6Section 08, Peter FrancisDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 426,993. Filing ↗machine: span 304715–304722
7Section 08, Edward F. SmithDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 424,910. Filing ↗machine: span 307243–307250
8Section 08, Kishen MehtaDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 368,410. Filing ↗machine: span 305514–305521
9Section 08, Dr. Jerel BanksDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 0. Filing ↗
10Section 08, Megan BostonDEF 14A2025-10-140001193125-25-239131Section “Director Compensation”. As printed: 0. Filing ↗
11Section 06, 2025 voteForm 8-K2025-12-020001193125-25-305475Item 5.07 · say-on-pay result. As reported: 77.73% (votes for as printed: 17,239,339). Filing ↗
12Section 06, 2024 voteForm 8-K2024-12-060001193125-24-272533Item 5.07 · say-on-pay result. As reported: 99.96% (votes for as printed: 17,307,680). Filing ↗
13Section 06, 2023 voteForm 8-K2023-12-070001193125-23-290709Item 5.07 · say-on-pay result. As reported: 96.24% (votes for as printed: 1,327,852). Filing ↗
14Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
15Section 09b board cost (computed)Computed——Cash 173,042 + equity 0 + all other 6,041 = 179,083, summed across the director compensation table rows.machine: formula: Σ = 179,083
16Benitec Biopharma (subject), Section 10b CEO totalDEF 14A2025-10-140001193125-25-239131CEO total compensation as printed in Benitec Biopharma's own proxy. As printed: 25,865,036. Filing ↗machine: r2 · c22 · span 187662–187672

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.